US FDA issues Emergency Use Authorization (EUA) allowing hydroxychloroquine and chloroquine to be used to treat COVID-19

The FDA notes there are no robust clinical data to confirm effectiveness of these drugs for COVID19. Separately, the MHRA had issued a statement advising until clear evidence to show these treatments are safe/effective for COVID19, they should only be used within a clinical trial

SPS commentary:

The MHRA had issued a statement advising that chloroquine and hydroxychloroquine are not licensed to treat COVID19 related symptoms or prevent infection. Clinical trials are ongoing to test chloroquine and hydroxychloroquine as an agent in the treatment of COVID19 or to prevent COVID19 infection.


Biospace Inc.

Resource links:

MHRA (25 March 2020)